EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Complement system in cancer: friend or foe of immunotherapy

Harendra Kumar Shah, Sai Prem, Xiaobo Wu, M Kathryn Liszewski, John P Atkinson, Abhay Kumar Singh, Vaishali Kapoor

Journal for ImmunoTherapy of Cancer · 2026

DOI: 10.1136/jitc-2025-013290 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Harendra Kumar Shah und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Washington University in St Louis School of Medicine, St Louis, Missouri, USA. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, Complement System Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 194 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Department of Radiation Oncology, School of Medicine, Washington University in St. Louis, National Institute of General Medical Sciences, American Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The complement system, a key component of the immune response, plays a dual role in cancer, influencing both tumor suppression and progression. Its three activation pathways (classical, alternative, and lectin) initiate immune processes, including opsonization and cell lysis. Within the tumor microenvironment, however, complement activation can paradoxically support immune-mediated tumor control or contribute to immune evasion and tumor growth. Therapeutic interventions such as radiation and certain chemotherapies can trigger complement activation by inducing immunogenic cell death and the release of damage-associated molecular patterns. This activation leads to the generation of anaphylatoxins C3a and C5a, which recruit immune cells to the tumor site and promote antitumor immunity. However, these same fragments may also foster an immunosuppressive microenvironment by attracting regulatory T cells and myeloid-derived suppressor cells, thereby limiting the efficacy of immunotherapies. Additionally, tumor cells often upregulate membrane complement regulatory proteins, including CD46, CD55, and CD59, to escape complement-mediated cytotoxicity and immune surveillance. Recent insights indicate that the complement system is a critical barrier to effective immunotherapy. Complement inhibition, particularly by targeting C3a receptor and C5a receptor 1, has been shown to synergize with immune checkpoint inhibitors (eg, anti-programmed cell death protein-1/programmed death-ligand 1), reversing complement-driven immunosuppression and enhancing T cell–mediated tumor rejection. Combining complement blockade with proimmunogenic therapies such as radiation or chemotherapy may further amplify these effects by uncoupling therapy-induced complement activation from its immunosuppressive consequences. Thus, the interplay between complement activation and cancer therapeutics presents a promising avenue for treatment innovations. Strategic modulation of complement, whether through genetic, pharmacologic, or antibody-based approaches, could sensitize tumors to immunotherapy and help overcome resistance mechanisms. Continued investigation into this crosstalk will be essential for designing effective combination strategies that maximize antitumor immunity while minimizing immune escape.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyNeoplasmsComplement System ProteinsHumansAnimalsComplement ActivationTumor Microenvironment

Stichwörter der Autor:innen

ComplementImmune modulatoryImmunotherapyRadiotherapy/radioimmunotherapyTumor microenvironment - TME

Substanzen

Complement System Proteins

Autor:innen und Institutionen

  • Department of Radiation Oncology, Washington University in St Louis School of Medicine, St Louis, Missouri, USA.
  • Division of Rheumatology, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, Missouri, USA.
  • MilliporeSigma St Louis, St Louis, Missouri, USA.
  • Department of Radiation Oncology, Washington University in St Louis School of Medicine, St Louis, Missouri, USA vkapoor@wustl.edu.
  • Siteman Cancer Center, St Louis, Missouri, USA.

Förderung

  • Department of Radiation Oncology, School of Medicine, Washington University in St. Louis
  • National Institute of General Medical Sciences
  • American Cancer Society

Zitieren

APA

Shah, H. K., Prem, S., Wu, X., Liszewski, M. K., Atkinson, J. P., Singh, A. K., & Kapoor, V. (2026). Complement system in cancer: friend or foe of immunotherapy. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-013290

Vancouver

Shah HK, Prem S, Wu X, Liszewski MK, Atkinson JP, Singh AK, et al. Complement system in cancer: friend or foe of immunotherapy. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-013290

BibTeX
@article{Shah2026,
  author = {Shah, Harendra Kumar and Prem, Sai and Wu, Xiaobo and Liszewski, M Kathryn and Atkinson, John P and Singh, Abhay Kumar and Kapoor, Vaishali},
  title = {Complement system in cancer: friend or foe of immunotherapy},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  doi = {10.1136/jitc-2025-013290}
}
Kostenlos starten →